BACKGROUND: The degree of bariatric surgery (BS) induced vitamin D (VD) malabsorption is not well established. OBJECTIVE: The aim of this study is to evaluate the efficacy and safety of achieving 25-hydroxy VD (25(OH)D) levels ≥75 nmol/L with two regimens of VD supplementation after BS. METHODS: We performed two open-label, prospective studies in patients undergoing BS from 2009 to 2011. Postoperatively, all patients received Ca citrate 1,000 mg and 800 IU of VD3/day. In the first study, additional VD3 was prescribed according to preoperative 25(OH)D levels- < 25 nmol/L:2,800 IU/day; 26-50 nmol/L:2,000-1,200 IU/day, 51-62 nmol/L:1,000 IU; >63 nmol/L:0 IU/day-and we evaluated the patients at baseline and at 4 months. In the second study, an additional fixed high dose of 2,000 IU/day of VD3 was administered, and we evaluated patients at baseline and at 4 and 12 months after BS. RESULTS: The first study included 176 patients [mean age 44 (11)]; 140 were females. Before BS, 171 subjects (98 %) presented 25(OH)D levels <75 nmol/L. Postoperatively, the mean 25(OH)D levels increased from 40 (17) to 77 nmol/L (29) (p < 0.001) with no differences in parathormone (PTH) or 25(OH)D levels between dose groups. In the second study, we enrolled 52 patients [mean age 45 (10)]; 32 were females. Postoperatively, the mean 25(OH)D levels increased from 32 (12) to 80 (22) and to 75 nmol/L (15) (p < 0.001) at 4 and 12 months, respectively. In both studies, a high percentage of patients achieved 25(OH)D ≥75 nmol/L levels and no subject reported any serious adverse event. CONCLUSIONS: Both schedules of daily VD3 supplementation were effective and safe under conditions of clinical practice.
BACKGROUND: The degree of bariatric surgery (BS) induced vitamin D (VD) malabsorption is not well established. OBJECTIVE: The aim of this study is to evaluate the efficacy and safety of achieving 25-hydroxy VD (25(OH)D) levels ≥75 nmol/L with two regimens of VD supplementation after BS. METHODS: We performed two open-label, prospective studies in patients undergoing BS from 2009 to 2011. Postoperatively, all patients received Ca citrate 1,000 mg and 800 IU of VD3/day. In the first study, additional VD3 was prescribed according to preoperative 25(OH)D levels- < 25 nmol/L:2,800 IU/day; 26-50 nmol/L:2,000-1,200 IU/day, 51-62 nmol/L:1,000 IU; >63 nmol/L:0 IU/day-and we evaluated the patients at baseline and at 4 months. In the second study, an additional fixed high dose of 2,000 IU/day of VD3 was administered, and we evaluated patients at baseline and at 4 and 12 months after BS. RESULTS: The first study included 176 patients [mean age 44 (11)]; 140 were females. Before BS, 171 subjects (98 %) presented 25(OH)D levels <75 nmol/L. Postoperatively, the mean 25(OH)D levels increased from 40 (17) to 77 nmol/L (29) (p < 0.001) with no differences in parathormone (PTH) or 25(OH)D levels between dose groups. In the second study, we enrolled 52 patients [mean age 45 (10)]; 32 were females. Postoperatively, the mean 25(OH)D levels increased from 32 (12) to 80 (22) and to 75 nmol/L (15) (p < 0.001) at 4 and 12 months, respectively. In both studies, a high percentage of patients achieved 25(OH)D ≥75 nmol/L levels and no subject reported any serious adverse event. CONCLUSIONS: Both schedules of daily VD3 supplementation were effective and safe under conditions of clinical practice.
Authors: J Vidal; A Ibarzabal; J Nicolau; M Vidov; S Delgado; G Martinez; J Balust; R Morinigo; A Lacy Journal: Obes Surg Date: 2007-08 Impact factor: 4.129
Authors: Arthur M Carlin; D Sudhaker Rao; Ali M Meslemani; Jeffrey A Genaw; Nayana J Parikh; Shiri Levy; Arti Bhan; Gary B Talpos Journal: Surg Obes Relat Dis Date: 2006-02-28 Impact factor: 4.734
Authors: Jeffrey I Mechanick; Adrienne Youdim; Daniel B Jones; W Timothy Garvey; Daniel L Hurley; M Molly McMahon; Leslie J Heinberg; Robert Kushner; Ted D Adams; Scott Shikora; John B Dixon; Stacy Brethauer Journal: Obesity (Silver Spring) Date: 2013-03 Impact factor: 5.002
Authors: Erlend T Aasheim; Sofia Björkman; Torgeir T Søvik; My Engström; Susanna E Hanvold; Tom Mala; Torsten Olbers; Thomas Bøhmer Journal: Am J Clin Nutr Date: 2009-05-13 Impact factor: 7.045
Authors: E M Stein; G Strain; N Sinha; D Ortiz; A Pomp; G Dakin; D J McMahon; R Bockman; S J Silverberg Journal: Clin Endocrinol (Oxf) Date: 2008-11-05 Impact factor: 3.478
Authors: Maria Paula Carlini Cambi; Giorgio A P Baretta; Maurício Spagnol; Roberto Zilio; Carina Rossoni Journal: Obes Surg Date: 2019-03 Impact factor: 4.129
Authors: R Vilallonga; J L Pereira-Cunill; S Morales-Conde; I Alarcón; I Breton; E Domínguez-Adame; J V Ferrer; A Garcia Ruiz-de-Gordejuela; A Goday; A Lecube; E Martín García-Almenta; M Á Rubio; F J Tinahones; P P García-Luna Journal: Obes Surg Date: 2019-12 Impact factor: 4.129
Authors: Maria Luger; Renate Kruschitz; Christian Kienbacher; Stefan Traussnigg; Felix B Langer; Gerhard Prager; Karin Schindler; Enikö Kallay; Friedrich Hoppichler; Michael Trauner; Michael Krebs; Rodrig Marculescu; Bernhard Ludvik Journal: Obes Surg Date: 2017-05 Impact factor: 4.129
Authors: Mary O'Kane; Helen M Parretti; Jonathan Pinkney; Richard Welbourn; Carly A Hughes; Jessica Mok; Nerissa Walker; Denise Thomas; Jennifer Devin; Karen D Coulman; Gail Pinnock; Rachel L Batterham; Kamal K Mahawar; Manisha Sharma; Alex I Blakemore; Iris McMillan; Julian H Barth Journal: Obes Rev Date: 2020-08-02 Impact factor: 9.213